argenex SE $ARGX Shares Bought by Citigroup Inc.

Citigroup Inc. grew its holdings in argenex SE (NASDAQ:ARGX) by 17.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,533 shares of the company’s stock after purchasing an additional 815 shares during the quarter. Citigroup Inc.’s holdings in argenex were worth $4,081,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. GAMMA Investing LLC increased its holdings in shares of argenex by 6.8% in the third quarter. GAMMA Investing LLC now owns 251 shares of the company’s stock valued at $185,000 after purchasing an additional 16 shares during the last quarter. Portside Wealth Group LLC grew its holdings in argenex by 2.8% in the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock valued at $430,000 after buying an additional 16 shares in the last quarter. Cromwell Holdings LLC increased its stake in shares of argenex by 10.0% in the 3rd quarter. Cromwell Holdings LLC now owns 187 shares of the company’s stock worth $138,000 after acquiring an additional 17 shares during the last quarter. Wealth Alliance LLC raised its holdings in shares of argenex by 2.7% during the 3rd quarter. Wealth Alliance LLC now owns 839 shares of the company’s stock worth $619,000 after acquiring an additional 22 shares during the period. Finally, Main Management ETF Advisors LLC boosted its position in shares of argenex by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 1,466 shares of the company’s stock valued at $808,000 after acquiring an additional 24 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ARGX. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Robert W. Baird raised their price target on shares of argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Citizens Jmp upped their price objective on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday, February 27th. Citigroup lowered their price objective on argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Finally, Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $999.22.

argenex Stock Up 0.1%

Shares of NASDAQ ARGX opened at $749.56 on Thursday. The business’s 50 day moving average is $820.51 and its two-hundred day moving average is $814.08. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The firm has a market cap of $46.38 billion, a price-to-earnings ratio of 38.40, a PEG ratio of 1.27 and a beta of 0.38.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. argenex had a return on equity of 38.51% and a net margin of 30.42%.The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.